Compare SVC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVC | TECX |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 366.8M |
| IPO Year | N/A | 2018 |
| Metric | SVC | TECX |
|---|---|---|
| Price | $2.20 | $24.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.50 | ★ $80.40 |
| AVG Volume (30 Days) | ★ 1.9M | 284.0K |
| Earning Date | 02-25-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,873,944,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $13.70 |
| 52 Week High | $3.08 | $47.35 |
| Indicator | SVC | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 64.77 |
| Support Level | $1.95 | $21.33 |
| Resistance Level | $2.04 | $24.53 |
| Average True Range (ATR) | 0.08 | 1.81 |
| MACD | 0.01 | 0.43 |
| Stochastic Oscillator | 96.23 | 71.46 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its hotel investment unit and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza Hotels & Resorts, and Hyatt Place.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.